Delivery Order SPE2DB22D3016-SPE2DB25FAPD8
Award Date
2/25/25
Potential Completion Date
3/18/25
Potential Value
$48K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,019.28 firm fixed-price delivery order contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has an ultimate completion date of March 4, 2025 and was awarded on February 10, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp...
This federal contract award, valued at $46,236.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a critical prescription medication, to support DLA's medical supply chain. The contract has an ultimate completion date of September 20, 2024 and is a Firm Fixed Price Delivery Order. This award is likely part of a larger Indefinite Delivery Contract (IDC) that...
This federal contract award, valued at $23,118.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the drug OCREVUS 300 MG/10 ML VIAL 10ML, with a period of performance through November 12, 2024. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has a ceiling value of $54,395.32 and a completion date of October 10, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $120,192.80 firm fixed-price contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $69,354.24 and a completion date of August 9, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The contract has an award value of $12,019.28 and is a Firm Fixed Price Delivery Order, with a completion date of February 27, 2025. The contract covers the procurement of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS (ocrelizumab) 300 mg/10 ml vials. The $46,236.16 firm fixed-price delivery order has an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. This contract is likely part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract, valued at $92,472.32, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a U.S. government agency. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025,...